The scFv portion of CAR1 and CAR2 was engineered based on the anti-EGFR antibody mAb806, which recognizes the exposed epitope EGFR287–302 overexpressed on the tumor cell surface, as well as mutated EGFR. This evidence concerns the gene EGFR and neoplasm.